tiprankstipranks
Trending News
More News >

CSPC Pharmaceutical’s Meloxicam Injection Approved in China

Story Highlights
CSPC Pharmaceutical’s Meloxicam Injection Approved in China

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).

CSPC Pharmaceutical Group has announced that its Meloxicam Injection (Ⅲ), a nanocrystal product for intravenous administration, has received drug registration approval in China. This approval marks a significant advancement in the company’s product portfolio, enhancing its position in the analgesic treatment market and demonstrating a breakthrough in nanomedicine research.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company specializes in nanomedicine research and development, with a market focus on analgesic treatments.

YTD Price Performance: 61.51%

Average Trading Volume: 213,102,858

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$87.63B

Learn more about 1093 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1